Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating eloralintide, a drug given by injection, for its effects on body weight reduction in adults who are overweight or have obesity along with type 2 diabetes. The study aims to compare eloralintide with a placebo to assess its safety and effectiveness. Participation will last approximately 75 weeks, providing a thorough evaluation period. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all administered by subcutaneous injection once weekly. This phase 3, double-blind study ensures that neither participants nor researchers know which treatment is given, maintaining unbiased results. The treatment period lasts up to 64 weeks, with ongoing monitoring throughout. During the study, participants will have regular visits to assess changes in body weight, body fat, waist size, blood sugar control HbA1c, blood pressure, and other health markers. Questionnaires about physical function, eating behavior, and quality of life will also be collected. Safety will be monitored continuously, and the main measurement is the percent change in body weight at week 64 compared to the start. Participants involvement will last about 75 weeks in total.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, tolerability, and how the body processes a drug called ORX142 in healthy adults aged 18 to 80 years. This Phase 1 clinical trial includes several parts to study single and multiple doses, the effects of food on the drug, and tests in both younger and older adults, as well as in people who have been acutely sleep-deprived. The study aims to understand the drugs effects on excessive daytime sleepiness. Participants will receive ORX142 or placebo tablets in different parts of the study. Parts A, B, and C focus on single and multiple ascending doses in healthy adults, with Part B examining the food effect on the drug. Part D studies single doses in healthy older adults, while Part E tests the drug in acutely sleep-deprived healthy adults. The study uses a randomized, double-blind, placebo-controlled design. During the trial, participants will be closely monitored for side effects and treatment-emergent adverse events from enrollment until 13 days after discharge. Blood samples will be taken before and after dosing to measure drug levels and how the body processes it over time. Sleepiness will be assessed using tests like the Maintenance of Wakefulness Test and the Karolinska Sleepiness Scale in Part E. Overall participation duration varies depending on the part of the study involved.
Actively Recruiting
The trial investigates how well AZD6234 works and its safety in adults who have Type 2 Diabetes Mellitus along with obesity or excess weight. This Phase III, global, randomized, double-blind study compares AZD6234 to a placebo to measure changes in body weight over 68 weeks of treatment. The study aims to better understand weight loss effects and related health changes in this population. Participants will be randomly assigned to one of three groups two different doses of AZD6234 or a placebo. The treatments are given by weekly subcutaneous injections. The study will last 68 weeks, during which participants receive their assigned injections and are monitored regularly for effectiveness and safety. Throughout the study, participants will attend multiple visits for evaluations, including body weight, waist circumference, blood pressure, and lab tests such as haemoglobin A1C and triglycerides. Some may undergo DXA scans to measure fat mass. Researchers will track changes from baseline to assess weight loss and metabolic effects. Safety and tolerability will also be monitored over the treatment period, which lasts about 68 weeks.
Actively Recruiting
Researchers are evaluating the efficacy and safety of subcutaneous nomlabofusp in both adult and pediatric subjects with Friedreichs ataxia, a genetic condition. This is a global, randomized, multi-center, placebo-controlled Phase 3 study that aims to assess how nomlabofusp affects balance and overall disease severity compared to placebo over a period of 72 weeks. Participants will receive either a daily subcutaneous injection of nomlabofusp or a placebo for 72 weeks. The study includes two groups one receiving the active drug and the other receiving placebo injections. The study will measure changes in balance using the Upright Stability Score USS subscale E of the modified Friedreichs Ataxia Rating Scale mFARS and the total mFARS score, as well as the Clinical Global Impression of Severity CGI-S at multiple time points through Week 72. During the study, participants will undergo regular assessments at baseline and Weeks 12, 24, 36, 48, and 72. These evaluations include clinical scales measuring balance and disease severity. Safety and tolerability of nomlabofusp will also be monitored throughout. Participants must meet specific eligibility criteria including genetic confirmation of Friedreichs ataxia, performance on stability tests, and functional staging. The total duration of participation spans the 72-week treatment period with scheduled evaluations.
Actively Recruiting
Healthy Volunteer
Evaluating Safety, Tolerability, and Body Processing of JZP269 Compared to Placebo in Healthy Adults
Researchers are evaluating the safety, tolerability, pharmacokinetics PK, and pharmacodynamics PD of JZP269, an orexin-2 receptor agonist, in healthy male and female adults aged 18 to 55 years. This phase 1, randomized, double-blind, placebo-controlled study aims to understand how the drug behaves in the body, its effects on wakefulness, and the impact of food on its absorption and activity. Participants will be randomly assigned to receive either JZP269 or a matching placebo. The study includes single and multiple ascending doses of the drug to assess its safety and how it is processed in the body. Cerebrospinal fluid samples will be collected to measure drug exposure, and wake-promoting effects will be evaluated using the Maintenance of Wakefulness Test and the Karolinska Sleepiness Scale in sleep-deprived participants. During the study, participants will be monitored for adverse events, and blood samples will be taken up to 48 hours after dosing to analyze pharmacokinetic parameters such as maximum concentration and elimination half-life. Safety assessments include medical evaluations, laboratory tests, and cardiac monitoring. The total participation duration includes dosing days and a safety follow-up period extending up to 7 days after the last dose.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are studying Friedreichs ataxia FRDA, a condition affecting children aged 2 years and older, adolescents, and adults up to 60 years old. This open-label study evaluates the long-term safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and clinical effects of CTI-1601, a recombinant fusion protein designed to deliver the deficient human frataxin protein in FRDA patients. The study enrolls both patients who have and have not participated in prior CTI-1601 trials. Participants receive daily subcutaneous injections of CTI-1601. Those aged 18 years and older receive a fixed dose of 50 mg, while children and adolescents aged 2 to 17 years receive a weight-based dose of 0.8 mgkg up to a maximum of 50 mg. The treatment period lasts up to 24 months, during which safety, clinical, and biological effects are monitored closely. During the study, participants undergo regular assessments including monitoring of adverse events, heart function via electrocardiograms and echocardiograms, and neurological and motor function tests such as the modified Friedreichs Ataxia Rating Scale mFARS, 9-hole peg test, and timed 25-foot walk. Tissue frataxin levels are measured through cheek swabs and skin biopsies. Patient and clinician global impressions of change, activities of daily living, fatigue, and gene expression are also evaluated. Pharmacokinetic sampling occurs at multiple time points throughout the study to analyze drug exposure. The study lasts up to 24 months, with ongoing safety and clinical monitoring.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new approach to treating opioid use disorder OUD by studying a vaccine targeted against oxycodone, one of the commonly abused prescription opioids. This Phase 1a1b clinical trial aims to assess the safety, immune response, and effectiveness of the OxyGly4-sKLH vaccine in adults aged 18 to 59 years who meet criteria for moderate to severe OUD and are physically dependent on opioids. The study is supported by the New York State Psychiatric Institute and includes participants not currently seeking treatment for their opioid use. The study compares two doses of the OxyGly4-sKLH vaccine low and high dose to a placebo, administered by injection into the deltoid muscle at Weeks 0, 3, 6, and 18. Participants will be randomly assigned to one of these groups in a triple-masked design. The trial includes several phases a screening phase lasting from 6 to 2 weeks before vaccination, an outpatient study visit phase from Week 0 to Week 21, three laboratory sessions at Weeks -1, 7, and 19, and an extended follow-up period from Weeks 23 to 42. During the approximately 42-week participation, individuals will undergo safety monitoring for adverse events, assessments of immune response to the vaccine, and evaluations of the vaccines effect on drug liking after opioid administration. Assessments include blood tests for antibodies, urine drug screens, and subjective effect measures during testing sessions lasting up to 4.5 hours post-dose. Participants must comply with scheduled visits, dosing, and lab tests, with continuous monitoring for safety and immune response throughout the study.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
1-10 of 16
1